您当前所在的位置:首页 > 产品中心 > 产品信息
Cefdinir_分子结构_CAS_91832-40-5)
点击图片或这里关闭

Cefdinir

产品号 DB00535 公司名称 DrugBank
CAS号 91832-40-5 公司网站 http://www.ualberta.ca/
分子式 C14H13N5O5S2 电 话 (780) 492-3111
分子量 395.41352 传 真
纯 度 电子邮件 david.wishart@ualberta.ca
保 存 Chembase数据库ID: 417

产品价格信息

请登录

产品别名

标题
Cefdinir
IUPAC标准名
(6R,7R)-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(N-hydroxyimino)acetamido]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
IUPAC传统名
cefdinir
商标名
Cefzon
Omnicef
别名
Cefdirnir
CFDN

产品登记号

PubChem SID 46505573
CAS号 91832-40-5
PubChem CID 6915944

产品性质

疏水性(logP) -0.2

产品详细信息

详细说明 (English)
Item Information
Drug Groups approved
Description Cefdinir (marketed by Abbott Laboratories under the brand name Omnicef) is a semi-synthetic, broad-spectrum antibiotic in the third generation of the cephalosporin class, proven effective for common bacterial infections of the ear, sinus, throat, and skin. It was approved by the U.S. Food and Drug Administration (FDA) in December of 1997.
Indication For the treatment of the respiratory, skin, soft tissue, and ENT infections caused by H. influenzae (including b-lactamase producing strains), H. parainfluenzae (including b-lactamase producing strains), S. pneumoniae (penicillin-susceptible strains), S. pyogenes, S. aureus (including b-lactamase producing strains), and M. catarrhalis.
Pharmacology Cefdinir is a third generation cephalosporin with a broad spectrum of activity against enteric gram-negative rods. Cefdinir is stable in the presence of some, but not all, b-lactamase enzymes. As a result, many organisms resistant to penicillins and some cephalosporins are susceptible to cefdinir. Cephalosporins work the same way as penicillins: they interfere with the peptidoglycan synthesis of the bacterial wall by inhibiting the final transpeptidation needed for the cross-links. This effect is bactericidal.
Toxicity Information on cefdinir overdosage in humans is not available. In acute rodent toxicity studies, a single oral 5600-mg/kg dose produced no adverse effects. Toxic signs and symptoms following overdosage with other b-lactam antibiotics have included nausea, vomiting, epigastric distress, diarrhea, and convulsions.
Affected Organisms
Enteric gram-negative rods
Biotransformation Cefdinir is not appreciably metabolized. Activity is primarily due to parent drug.
Absorption Maximal plasma cefdinir concentrations occur 2 to 4 hours postdose following capsule or suspension administration. Estimated bioavailability of cefdinir capsules is 21% following administration of a 300 mg capsule dose, and 16% following administration of a 600 mg capsule dose. Estimated absolute bioavailability of cefdinir suspension is 25%. Absorption is reduced by approximately 15% when administered with a high fat meal.
Half Life 1.7 ± 0.6 hours
Protein Binding 60%-70%, binding is independent of concentration.
Elimination Cefdinir is not appreciably metabolized. Cefdinir is eliminated principally via renal excretion with a mean plasma elimination half-life (t?) of 1.7 (±0.6) hours.
Distribution * 0.35±0.29 L/kg [adult subjects]
* 0.67±0.38 L/kg [pediatric subjects (age 6 months to 12 years)]
Clearance * renal cl=2 +/- 1 mL/min/kg [healthy]
References
Yamanaka H, Shimazaki J, Imai K, Sugiyama Y, Shida K: Effect of estrogen administration on activities of testosterone 5alpha-reductase, alkaline phosphatase and arginase in the ventral and the dorsolateral prostates of rats. Endocrinol Jpn. 1975 Aug;22(4):297-302. [Pubmed]
External Links
Wikipedia
RxList
PDRhealth
Drugs.com

参考文献

  • Yamanaka H, Shimazaki J, Imai K, Sugiyama Y, Shida K: Effect of estrogen administration on activities of testosterone 5alpha-reductase, alkaline phosphatase and arginase in the ventral and the dorsolateral prostates of rats. Endocrinol Jpn. 1975 Aug;22(4):297-302. Pubmed